Esophageal Cancer Stem Cells and Implications for Future Therapeutics

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2016 May 5

PMID 27143920

Citations 16

Authors

Xia Qian

Cheng Tan

Feng Wang

Baixia Yang

Yangyang Ge

Zhifeng Guan

Jing Cai

Affiliations

Soon will be listed here.

Abstract

Esophageal carcinoma (EC) is a lethal disease with high morbidity and mortality worldwide, and the incidence has been increasing in recent years. Although the diagnosis and treatment of EC have improved considerably, EC has rapidly progressed in the clinical setting and has a poor prognosis for its metastasis and recurrence. The general idea of cancer stem cells (CSCs) is primarily based on clinical and experimental observations, indicating the existence of a subpopulation of cells that can self-renew and differentiate. The EC stem cells, which can be isolated from normal pluripotent stem cells by applying similar biomarkers, may participate in promoting esophageal tumorigenesis through renewal and repair. In this review, major emphasis is given to CSC markers, altered CSC-specific pathways, and molecular targeting agents currently available to target CSCs of esophageal cancer. The roles of numerous markers (CD44, aldehyde dehydrogenase, CD133, and ATP-binding cassette subfamily G member 2) and developmental signaling pathways (Wnt/β-catenin, Notch, hedgehog, and Hippo) in isolating esophageal CSCs are discussed in detail. Targeting CSCs can be a logical strategy to treat EC, as these cells are responsible for carcinoma recurrence and chemoradiation resistance.

Citing Articles

Surface Markers for the Identification of Cancer Stem Cells.

Pronoy T, Islam F, Gopalan V, Lam A Methods Mol Biol. 2024; 2777:51-69.

PMID: 38478335 DOI: 10.1007/978-1-0716-3730-2_4.

Prediction of recurrence free survival for esophageal cancer patients using a protein signature based risk model.

Hasan R, Srivastava G, Alyass A, Sharma R, Saraya A, Chattopadhyay T Oncotarget. 2022; 13:1020-1032.

PMID: 36128326 PMC: 9477219. DOI: 10.18632/oncotarget.10656.

Targeting Strategies for Aberrant Lipid Metabolism Reprogramming and the Immune Microenvironment in Esophageal Cancer: A Review.

Cui M, Yi X, Cao Z, Zhu D, Wu J J Oncol. 2022; 2022:4257359.

PMID: 36106333 PMC: 9467784. DOI: 10.1155/2022/4257359.

Aprepitant Promotes Caspase-Dependent Apoptotic Cell Death and G2/M Arrest through PI3K/Akt/NF-B Axis in Cancer Stem-Like Esophageal Squamous Cell Carcinoma Spheres.

Javid H, Afshari A, Avval F, Asadi J, Hashemy S Biomed Res Int. 2021; 2021:8808214.

PMID: 34926694 PMC: 8677400. DOI: 10.1155/2021/8808214.

The tumour immune microenvironment in oesophageal cancer.

Davern M, Donlon N, Power R, Hayes C, King R, Dunne M Br J Cancer. 2021; 125(4):479-494.

PMID: 33903730 PMC: 8368180. DOI: 10.1038/s41416-021-01331-y.

References

Ishiguro S, Sasazuki S, Inoue M, Kurahashi N, Iwasaki M, Tsugane S . Effect of alcohol consumption, cigarette smoking and flushing response on esophageal cancer risk: a population-based cohort study (JPHC study). Cancer Lett. 2008; 275(2):240-6. DOI: 10.1016/j.canlet.2008.10.020. View

Storms R, Trujillo A, Springer J, Shah L, COLVIN O, Ludeman S . Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci U S A. 1999; 96(16):9118-23. PMC: 17742. DOI: 10.1073/pnas.96.16.9118. View

Lu C, Guo J, Gu J, Ge D, Hou Y, Lin Z . CXCR4 heterogeneous expression in esophageal squamous cell cancer and stronger metastatic potential with CXCR4-positive cancer cells. Dis Esophagus. 2013; 27(3):294-302. DOI: 10.1111/dote.12100. View

Tsai S, Wang P, Liou N, Lin P, Chen C, Chang W . ICAM1 Is a Potential Cancer Stem Cell Marker of Esophageal Squamous Cell Carcinoma. PLoS One. 2015; 10(11):e0142834. PMC: 4646358. DOI: 10.1371/journal.pone.0142834. View

Zhang G, Ma L, Xie Y, Miao X, Jin C . Esophageal cancer tumorspheres involve cancer stem-like populations with elevated aldehyde dehydrogenase enzymatic activity. Mol Med Rep. 2012; 6(3):519-24. DOI: 10.3892/mmr.2012.939. View

Lu C, Xu F, Gu J, Yuan Y, Zhao G, Yu X . Clinical and biological significance of stem-like CD133(+)CXCR4(+) cells in esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2015; 150(2):386-95. DOI: 10.1016/j.jtcvs.2015.05.030. View

Zhang D, Jiang A, Lu H, Zhang L, Gao X . Isolation, cultivation and identification of human lung adenocarcinoma stem cells. Oncol Lett. 2014; 9(1):47-54. PMC: 4246672. DOI: 10.3892/ol.2014.2639. View

von Rahden B, Kircher S, Lazariotou M, Reiber C, Stuermer L, Otto C . LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's esophagus?. J Exp Clin Cancer Res. 2011; 30:23. PMC: 3058063. DOI: 10.1186/1756-9966-30-23. View

Rassouli F, Matin M, Bahrami A, Ghaffarzadegan K, Cheshomi H, Lari S . Evaluating stem and cancerous biomarkers in CD15+CD44+ KYSE30 cells. Tumour Biol. 2013; 34(5):2909-20. DOI: 10.1007/s13277-013-0853-5. View

10.

Huang J, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A . YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene. 2012; 32(17):2220-9. PMC: 3443515. DOI: 10.1038/onc.2012.231. View

11.

Tang K, Dai Y, Tong M, Chan Y, Kwan P, Fu L . A CD90(+) tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer. Cancer Res. 2013; 73(7):2322-32. DOI: 10.1158/0008-5472.CAN-12-2991. View

12.

Clarke M, Dick J, Dirks P, Eaves C, Jamieson C, Jones D . Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006; 66(19):9339-44. DOI: 10.1158/0008-5472.CAN-06-3126. View

13.

Parkin D, Laara E, Muir C . Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer. 1988; 41(2):184-97. DOI: 10.1002/ijc.2910410205. View

14.

Jiang F, Qiu Q, Khanna A, Todd N, Deepak J, Xing L . Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009; 7(3):330-8. PMC: 4255559. DOI: 10.1158/1541-7786.MCR-08-0393. View

15.

Huang D, Gao Q, Guo L, Zhang C, Jiang W, Li H . Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev. 2008; 18(3):465-73. DOI: 10.1089/scd.2008.0033. View

16.

Butof R, Dubrovska A, Baumann M . Clinical perspectives of cancer stem cell research in radiation oncology. Radiother Oncol. 2013; 108(3):388-96. DOI: 10.1016/j.radonc.2013.06.002. View

17.

Diehn M, Clarke M . Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst. 2006; 98(24):1755-7. DOI: 10.1093/jnci/djj505. View

18.

Filipovic A, Stebbing J, Giamas G . Cancer stem cells--therapeutic targeting or therapy?. Lancet Oncol. 2013; 14(7):579-80. DOI: 10.1016/S1470-2045(13)70258-4. View

19.

Mao B, Hu F, Cheng J, Wang P, Xu M, Yuan F . SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene. 2013; 33(11):1468-74. DOI: 10.1038/onc.2013.88. View

20.

Marson A, Foreman R, Chevalier B, Bilodeau S, Kahn M, Young R . Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell. 2008; 3(2):132-5. PMC: 3235673. DOI: 10.1016/j.stem.2008.06.019. View